Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price was up 15.4% during mid-day trading on Wednesday . The stock traded as high as C$0.24 and last traded at C$0.23. 501,343 shares traded hands during mid-day trading, a decline of 18% from the average daily volume of 612,724 shares. The stock had previously closed at C$0.20.
Hemostemix Stock Performance
The stock’s 50-day moving average is C$0.10 and its 200 day moving average is C$0.08. The stock has a market capitalization of C$19.17 million, a PE ratio of -11.00 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Quiet Period Expirations Explained
- How Do Stock Buybacks Affect Shareholders?
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- What Goldman Sachs’ Quarterly Results Reveal About the Economy
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
